替雷利珠单抗引起的胃反应性毛细血管瘤。 - Suppr

Suppr

超能文献

Gastric reactive capillary hemangioma caused by tislelizumab.

作者信息

Long Xin, Zhang Huipeng, Yin Tengfei, Zhang Jing, Yu Yanbo, Gao Yanjing

机构信息

Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Endoscopy. 2025 Dec;57(S 01):E941-E942. doi: 10.1055/a-2657-0108. Epub 2025 Aug 20.

DOI:10.1055/a-2657-0108

PMID:40834897

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12367400/

Abstract

摘要

相似文献

Gastric reactive capillary hemangioma caused by tislelizumab.

Endoscopy. 2025 Dec;57(S 01):E941-E942. doi: 10.1055/a-2657-0108. Epub 2025 Aug 20.

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.

Front Public Health. 2023 Feb 24;11:1051484. doi: 10.3389/fpubh.2023.1051484. eCollection 2023.

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report.

Front Oncol. 2023 May 10;13:1147636. doi: 10.3389/fonc.2023.1147636. eCollection 2023.

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.

Front Immunol. 2023 May 4;14:1122121. doi: 10.3389/fimmu.2023.1122121. eCollection 2023.

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.

BMC Health Serv Res. 2024 May 29;24(1):676. doi: 10.1186/s12913-024-11142-5.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.

Curr Med Res Opin. 2025 Jun;41(6):1007-1016. doi: 10.1080/03007995.2025.2501588. Epub 2025 Jun 18.

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13.

Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report.

World J Clin Cases. 2020 Feb 6;8(3):624-629. doi: 10.12998/wjcc.v8.i3.624.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.

BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876.

Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer.

Front Oncol. 2024 Sep 5;14:1425572. doi: 10.3389/fonc.2024.1425572. eCollection 2024.

本文引用的文献

An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.

Oral Oncol. 2023 May;140:106369. doi: 10.1016/j.oraloncology.2023.106369. Epub 2023 Mar 28.

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.

BMC Oral Health. 2021 Nov 2;21(1):559. doi: 10.1186/s12903-021-01901-9.

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.

J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验